- Home
- PCRX vs NDMO Comparison
PCRX vs NDMO Comparison
Compare PCRX & NDMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- NDMO
- Stock Information
- Founded
- PCRX 2006
- NDMO 2019
- Country
- PCRX United States
- NDMO United States
- Employees
- PCRX N/A
- NDMO N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- NDMO Trusts Except Educational Religious and Charitable
- Sector
- PCRX Health Care
- NDMO Finance
- Exchange
- PCRX Nasdaq
- NDMO Nasdaq
- Market Cap
- PCRX 1.2B
- NDMO 620.6M
- IPO Year
- PCRX 2011
- NDMO N/A
- Fundamental
- Price
- PCRX $26.00
- NDMO $10.43
- Analyst Decision
- PCRX Buy
- NDMO
- Analyst Count
- PCRX 6
- NDMO 0
- Target Price
- PCRX $30.00
- NDMO N/A
- AVG Volume (30 Days)
- PCRX 605.6K
- NDMO 218.6K
- Earning Date
- PCRX 11-05-2025
- NDMO 01-01-0001
- Dividend Yield
- PCRX N/A
- NDMO 6.75%
- EPS Growth
- PCRX N/A
- NDMO N/A
- EPS
- PCRX N/A
- NDMO N/A
- Revenue
- PCRX $705,848,000.00
- NDMO N/A
- Revenue This Year
- PCRX $7.36
- NDMO N/A
- Revenue Next Year
- PCRX $10.07
- NDMO N/A
- P/E Ratio
- PCRX N/A
- NDMO N/A
- Revenue Growth
- PCRX 2.25
- NDMO N/A
- 52 Week Low
- PCRX $13.04
- NDMO $8.99
- 52 Week High
- PCRX $27.64
- NDMO $11.24
- Technical
- Relative Strength Index (RSI)
- PCRX 51.09
- NDMO 52.61
- Support Level
- PCRX $26.22
- NDMO N/A
- Resistance Level
- PCRX $27.50
- NDMO $9.98
- Average True Range (ATR)
- PCRX 0.92
- NDMO 0.11
- MACD
- PCRX -0.15
- NDMO -0.34
- Stochastic Oscillator
- PCRX 18.41
- NDMO 99.52
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest
Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. Its investment objective is to seek total return through income exempt from regular federal income taxes and capital appreciation. A majority of its investments are made in municipal securities, the income from which is exempted from regular federal income taxes.